Related Experiment Video
Updated: Nov 15, 2025
14:55
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
Published on: December 3, 2013
7.4K
Viral Vectors for COVID-19 Vaccine Development
1PanTherapeutics, CH1095 Lutry, Switzerland.
Viruses
|March 6, 2021
Summary
Various viral vectors, including adenovirus-based ones, are being developed as COVID-19 vaccines. Adenovirus vectors have shown promise in animal studies and clinical trials, with one approved for human use.
Area of Science:
- Virology
- Vaccinology
- Immunology
Background:
- The COVID-19 pandemic necessitated rapid vaccine development.
- Viral vectors, particularly adenovirus vectors, are key platforms for vaccine candidates.
Purpose of the Study:
- To review the development of viral vector-based vaccines against SARS-CoV-2.
- To highlight the role of adenovirus vectors in COVID-19 vaccine research.
Main Methods:
- Exploration of various viral vector systems (adenovirus, vaccinia, measles, etc.).
- Focus on adenovirus-based vectors for SARS-CoV-2 vaccine development.
- Review of preclinical and clinical trial data for adenovirus-based vaccines.
Main Results:
- Adenovirus-based vaccine candidates have demonstrated robust immune responses in animals.
- Protection against SARS-CoV-2 challenge has been achieved in mice and primates.
- Multiple adenovirus-based vaccine candidates have progressed through Phase I-III clinical trials.
Conclusions:
- Adenovirus vectors are a successful platform for SARS-CoV-2 vaccine development.
- The ChAdOx1 simian adenovirus vector has been approved for human use in the UK.
- Viral vector technology plays a crucial role in addressing global health emergencies.
